Skip to main content

Rabeprazole Disease Interactions

There are 4 disease interactions with rabeprazole.

Major

PPIs (applies to rabeprazole) C. diff

Major Potential Hazard, Moderate plausibility. Applicable conditions: Pseudomembranous Colitis, Diarrhea

Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve. It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile. C. difficile produces toxins A and B, which contribute to the development of CDAD. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

References

  1. "Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc (2022):
  2. "Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc PROD (2001):
  3. "Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals PROD (2001):
  4. "Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories PROD (2001):
  5. "Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories PROD
  6. "Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America (2009):
  7. "Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals (2014):
  8. "Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals (2014):
View all 8 references
Moderate

Proton pump inhibitors (applies to rabeprazole) bone fractures

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Osteoporosis

Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine. The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.

References

  1. "Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc PROD (2001):
  2. "Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals PROD (2001):
  3. "Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories PROD (2001):
  4. "Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals PROD (2001):
  5. "Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc (2003):
  6. "Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America (2009):
  7. "Product Information. Voquezna (vonoprazan)." Phathom Pharmaceuticals, Inc (2023):
View all 7 references
Moderate

Proton pump inhibitors (applies to rabeprazole) hypomagnesemia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Magnesium Imbalance

Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy. Serious adverse events can include tetany, seizures, and arrhythmias. Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics). Regular monitoring is recommended.

References

  1. "Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc PROD (2001):
  2. "Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals PROD (2001):
  3. "Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories PROD (2001):
  4. "Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals PROD (2001):
  5. "Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc (2003):
  6. "Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America (2009):
View all 6 references
Moderate

Rabeprazole (applies to rabeprazole) liver disease

Moderate Potential Hazard, Moderate plausibility.

Rabeprazole is primarily metabolized by the liver. Although the drug is generally well-tolerated, therapy with rabeprazole should be administered cautiously in patients with severe liver disease because of the lack of clinical data concerning its use in such patients. Dosage adjustments are not necessary in patients with mild to moderate hepatic impairment.

References

  1. Hoyumpa AM, Trevino-Alanis H, Grimes I, Humphries TJ "Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis." Clin Ther 21 (1999): 691-701
  2. Prakash A, Faulds D "Rabeprazole." Drugs 55 (1998): 261-7;disc. 268
  3. "Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals PROD (2001):

Rabeprazole drug interactions

There are 166 drug interactions with rabeprazole.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.